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Abstract
Background: Insulin resistance (IR) is induced by chronic hepatitis C virus (HCV) genotypes 1 and 4 infections. It is not
known whether drugs that affect IR such as Pioglitazone and Prednisone also affect serum HCV RNA titers independently of
PEG-Interferon-a2/ribavirin treatment. The primary aim was to assess whether Pioglitazone by improving IR and/or
inflammation decreases HCV viral load independently of standard of care HCV treatment. A secondary aim was to assess
whether Prednisone, a drug that induces insulin resistance and stimulates HCV viral entry and replication in replicon culture
systems, increases HCV viral load in this population.
Methodology/Principal Findings: We designed a two-arm, parallel Pilot Study of overweight, treatment naı ¨ve genotype 4
HCV-infected patients at a public referral Liver Clinic in Giza, Egypt. The subjects received Pioglitazone (30 mg/day for 14
days) or Prednisone (40 mg/day for 4 days) in a randomized fashion, but the two arms can be considered independent pilot
studies. Only changes from baseline within each arm were assessed and no contrasts of the interventions were made, as this
was not an aim of the study. Among 105 consecutive HCV genotype 4 patients, 39 were enrolled based on the optimal
sample size and power analysis according to the CONSORT statement; 20 to the Pioglitazone group and 19 to the
Prednisone group. Pioglitazone was effective in decreasing serum HCV RNA at day-14 (n=10; difference of
means=205,618 IU/ml; 95% CI 26,600 to 384,600; P,0.001). Although Prednisone did increase serum HCV RNA at day-4
(n=10; change from baseline=242,786 IU/ml; 95% CI 285,500 to 215,700; P=0.049), the log10 HCV RNA titers were
statistically not different from baseline day-0.
Conclusion/Significance: This is the first documentation that Pioglitazone decreases the serum HCV RNA titers
independently of PEG-Interferon-a2/ribavirin treatment. The novel findings of our Study provide the foundation for basic
and clinical investigations on the molecular mechanisms responsible for the Pioglitazone-induced decrease in HCV
genotype 4 RNA titers.
Trial Registration: ClinicalTrials.gov NCT01157975
Citation: Chojkier M, Elkhayat H, Sabry D, Donohue M, Buck M (2012) Pioglitazone Decreases Hepatitis C Viral Load in Overweight, Treatment Naı ¨ve, Genotype 4
Infected-Patients: A Pilot Study. PLoS ONE 7(3): e31516. doi:10.1371/journal.pone.0031516
Editor: John E. Tavis, Saint Louis University, United States of America
Received September 14, 2011; Accepted January 9, 2012; Published March 7, 2012
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: This trial was supported by discretionary funds from the University of California, San Diego and the Agouza Hospital, Ministry of Health, Giza, Egypt.
Additional support was from grants from the National Institutes of Health (RC1 Challenge-DK 087031; MERIT R37-DK-46071; R01-DK-38652, R01-DK-084139 and K-
22-CA-96932), and the Department of Veterans Affairs (Merit Review). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mchojkier@ucsd.edu
Introduction
Chronic hepatitis C viral (HCV) infection markedly increased
the risk for type 2 diabetes in cohorts with recognized diabetes
risk factors [1]. A meta-analysis also found that HCV infection is
associated with excess type 2 diabetes risk [2]. Moreover, IR is a
specific feature of chronic HCV genotypes 1 and 4 infections
since its prevalence is ,7-fold higher among these patients
compared to chronic Hepatitis B-infected patients [3], and
changes in IR occur among patients with chronic HCV infection
during and after treatment of HCV with PEG-interferon-a and
ribavirin [4].
In patients with genotypes 1, 2 and 3 increased IR was
associated with decreased sustained virological response (SVR) [5].
Among patients infected with genotype 1, decreases in Homeo-
stasis Model Assessment (HOMA)-IR correlated with obtaining an
SVR and increases in HOMA-IR were observed in patients who
relapsed [6]. Similarly, IR may correlate with the virological
response to standard of care treatment of HCV genotype 4
patients in Egypt [7].
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e31516Because Pioglitazone, a peroxisome proliferator-activated
receptor (PPAR)-c agonist, improves insulin sensitivity [8] and it
is also effective in controlling liver inflammation in subjects with
non-alcoholic steatohepatitis (NASH) [9], it has been used as triple
therapy in addition to PEG-interferon-a and ribavirin to treat
HCV-infected patients. The study in HCV genotype 1 non-
responders was terminated when none of the five patients
responded to the triple therapy at week 12 [10]. In contrast,
Pioglitazone improved virological response to PEG-interferon a-
2b/ribavirin combination therapy in hepatitis C genotype 4
treatment naı ¨ve patients with insulin resistance [11].
However, the mechanisms by which Pioglitazone influenced
SVR in treatment naı ¨ve patients with HCV genotype 4 infection
remain unknown. It is unknown whether Pioglitazone modifies the
bioavailability of PEG-interferon a-2b/ribavirin or directly or
indirectly affects HCV infection and replication.
Therefore, we designed a Pilot Study to assess whether
Pioglitazone decreases HCV viral load in overweight HCV
genotype 4, treatment naı ¨ve patients independently of standard
of care PEG-interferon a-2b/ribavirin treatment. A secondary
end-point was to analyze whether Prednisone, a drug that induces
insulin resistance in susceptible patients [12] and stimulates HCV
viral entry and replication in replicon culture systems [13],
increases HCV viral load in this population.
There were no data available on the effect of Pioglitazone or
Prednisone on HCV RNA viral load in patients. Here, we provide
the first documentation that Pioglitazone decreases the serum
HCV genotype 4 RNA titers independently of treatment with
PEG-Interferon-a2/ribavirin. Prednisone did increase serum
HCV RNA viral load at day-4 in this cohort.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Participants
Eligible participants were all overweight (BMI.25 kg/m
2), given
their susceptibility for IR,adults age 25to65 years, with active HCV
genotype 4 chronic infection (.10,000 IU/ml viral load) who had a
liver biopsy within two years of recruitment (added to the protocol),
were treatment naı ¨ve (never treated for HCV infection) and met the
eligibility criteria for the Study. Exclusion criteria included cirrhosis,
the presence of other liver diseases, diabetes, pregnancy, significant
clinical co-morbidities, and the inability to provide informed
consent. Participants were recruited from July 2010 to February
2011 at the primary care referral of subjects of a disadvantaged
social-economical group at the Agouza Hospital in Giza, Egypt. The
estimated prevalence of Hepatitis C in Egypt is 12% in adults.
Ethics
Written informed consent was obtained by the medical staff
before entry into the Study. The study was registered at the
clinicaltrials.gov website (NCT-01157975) and received Human
Subjects’ Research approval at the University of California, San
Diego (UCSD Human Research protections Program) and at the
Agouza Hospital, Giza, Egypt (Director’s Research Board) before
starting the study. The study protocol conforms to the ethical
guidelines of the 1975 Declaration of Helsinki.
Objectives
Because the objective of the Study was to determine whether
Pioglitazone and Prednisone treatment would affect the HCV
RNA viral load (decrease and increase it, respectively), and these
were not a treatment of the HCV infection in this situation, we
decided not to use a placebo since we utilized de-identified samples
to blinding the investigators analyzing the outcomes.
Interventions
Eligible subjects were randomly assigned to receive orally
Pioglitazone 30 mg/day for 14 days or Prednisone 40 mg/day for
4 days. These medications were taken in the morning. Visits were
at screening (up to 30 days before randomization); randomization
(day -2); baseline visit (day 0); and follow-up visits for the
Pioglitazone group (on days 2, 4, 7 and 14) and the Prednisone
group (on days 2 and 4). For safety issues subjects were continued
to be seen off protocol at day-7 post-treatment. Blood samples
were obtained at each visit for HCV RNA viral load and for
inflammatory, adipogenic, and insulin resistance markers. In
addition, a 2-hr oral 75 g glucose tolerance test (OGTT) was
performed after a 10-hr fast at day-0 before administration of the
medication and at the last day of treatment (day-14 for
Pioglitazone and day-4 for Prednisone). On all other visits,
patients were also fasting. Patients received the first dose of the
study drug (oral Pioglitazone 30 mg or Prednisone 40 mg) after
blood samples were obtained on day 0. Compliance with the
medication was .90% as assessed at each visit.
Outcomes
The primary outcome with respect to the effect of Pioglitazone
in HCV genotype 4 infections was the decrease in HCV RNA
viral load at day 14. The secondary outcome with respect to the
effect of Prednisone in HCV genotype 4 infections was the
increase in HCV RNA viral load at day 4 instead of at day 14 for
safety reasons given the potential adverse events associated with
longer corticosteroid treatment.
Additional secondary outcome measures were insulin resis-
tance (oral glucose tolerance test; serum insulin, C-peptide;
HOMA-IR; insulin sensitivity check index (QUICKI); HOMA-B;
sex hormone BG (SHBG); resistin; adiponectin) and liver injury
(alanine aminotransferase (ALT); aspartate aminotransferase
(AST)) and inflammation (serum interleukin (IL)-8, IL-28B,
tumor necrosis factor (TNF), IL-1a,I L - 1 b, IL-6, IL-8, IL-10,
IFN-c, monocyte chemokine protein (MCP) and hepatocyte
growth factor (HGF)).
De-identified blood samples from all the enrolled subjects that
received the treatments were analyzed for the standard clinical
laboratory tests and for HCV RNA viral load using PCR
amplification (COBAS, TACKMAN) (lowest detectable limit:
50 IU/ml).
A multiplex peptide detection system (Quansys Biosciences,
Logan, UT) was utilized according to the manufacturer’s protocol
to determine inflammatory, adipogenic, and insulin resistance
markers. Values calculated from individual pixels using the Q-
View Imager system. An enzyme-linked immunosorbent assay kit
was used to determine human adiponectin according to the
manufacturer’s protocol (BioVision, Mountain View, CA).
Surrogate indicators of insulin resistance and b-cell function
were analyzed as described previously [14]. The indicators of
insulin resistance HOMA1-IR and QUICKI were determined.
HOMA1-IR=(FSI6FSG)/22.5 where FSI is fasting serum insulin
concentration (mU/l) and FSG is fasting serum glucose (mmol/l).
QUICKI=1/[log (fasting insulin-mU/ml)+log (fasting glucose-
mg/dl)]. b-Cell function was assessed by the HOMA –B 20.I0/(G0
-3.5); I0=fasting insulin in mU/ml and G0=fasting glucose in
mmol/l [14].
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There were no data available on the effect of Pioglitazone or
Prednisone on HCV RNA viral load. However, we considered a
reduction of 25% in HCV RNA viral load in 14 days to be relevant
as proof of principle of the effects of Pioglitazone on HCV RNA
titers. To detect a reduction of 25% in HCV RNA in the
Pioglitazone group at day-14 assuming a standard deviation of 20%
with a two-sided 5% significance level and a power of 90%, a
sample size of 9 patients per group completing the study was
necessary, and it was decided to enroll at least 19 subjects per group
given an anticipated dropout rate of 50% mainly prior to dosing.
Because the cultural environment (unwillingness to tell the research
staff that they cannot participate in the study) and the social
conditions (such as severe problems with transportation and
employer’s authorization) were expected to prevent a significant
proportion of patients to attend the Clinic for follow-up visits after
randomization, a larger number of eligible subjects were random-
ized to achieve the desirable number of subjects completing the
Study. To recruit this number of patients a 12-month inclusion
period was anticipated. No interim analysis was performed during
the trial. An intention-to-treat analysis was conducted in patients
who had received $1 dose of study medication (10 patients in each
group was optimal based on sample size and power analysis).
Randomization—Sequence generation
Participants were randomly assigned following simple random-
ization procedures (computerized random numbers) to one of two
treatment groups. Independent pharmacists dispensed either
Pioglitazone or Prednisone according to a computer generated
randomization list.
Randomization—Allocation concealment
The decision to accept or reject a participant was made, and
informed consent was obtained from the participant, in ignorance
of the next assignment in the sequence.
Randomization—Implementation
Block randomization was by a computer generated random
number list prepared by a pharmacist with no clinical involvement
in the trial. After the research nurse had obtained the subject’s
consent, she contacted the pharmacist who was independent of the
recruitment process for allocation consignment.
Blinding
Whereas patients and physicians allocated to the intervention
groups were aware of the allocated arm, outcome assessors and
data analysts of primary and secondary end-points were kept
blinded to the allocation.
Statistical methods
An intention-to-treat analysis was conducted in patients who had
received $1 dose of study medication. The primary and secondary
endpoints were assessed with a paired-samplet-test.Wealso explored
correlations between IL8 and TNFa using Pearson’s correlation
coefficient with 95% confidence intervals. The significance level was
fixed at a=5% for all tests. All analyses were carried using R version
2.12.2 (2011 Vienna, Austria; http://www.R-project.org).
Results
Participant Flow
The optimal subjects’ recruitment number was pre-determined
by sample size and power analysis as described above. One
hundredth and five consecutive patients with chronic Hepatitis C
genotype 4 referred to the Hepatology Clinic were assessed for
eligibility (Fig. 1). Among these 105 patients, 66 were excluded
because they did not meet the eligibility criteria (42 subjects), they
refused to participate (8 subjects), or for other reasons (16 subjects).
Therefore, 39 patients were randomized; 20 to the Pioglitazone
group and 19 to the Prednisone group. Ten patients in each group
received the allocated intervention, while 10 patients in the
Pioglitazone group and 9 patients in the Prednisone group were
unable to participate because of their inability to attend the Clinic
visits. These patients did not receive the allocated intervention
(Fig. 1). The randomized groups that received the allocated
intervention were balanced in regards to age, gender, HCV
genotype and titers and the severity of their liver disease (Table 1).
The patients that did receive the allocated intervention were
similar in demographics, ethnicity and degree of liver disease to
those that did not receive the allocated intervention (Table 2). By
chance allocation, the serum ALT was lower in the group that
received Prednisone than in the group that did not received the
allocated Prednisone (53 vs 69 IU/ml; P=0.012) (Tables 1 and
2).
No participant was excluded after randomization because they
were found not to meet eligibility criteria. All the patients allocated
to the interventions (10 in each arm) completed the study (Fig. 1).
Baseline demographic and clinical characteristics
An intention-to-treat analysis was conducted in patients who
had received $1 dose of study medication; all of these patients had
a subsequent efficacy observation (10 patients in each group). As
outlined in Table 1, all patients were middle age Egyptian Arabs,
predominantly males that had HCV genotype 4 with mild or
moderate inflammation (A1 and A2, respectively) and mild or
moderate fibrosis (F1 and F2, respectively) on their liver biopsy.
They had normal albumin and total bilirubin and mild increase in
ALT/AST. All subjects were overweight and five were obese
(body mass index, BMI; the weight in kg divided by the square of
the height in meters was .29 kg/m
2: 3 in the Pioglitazone group
and 2 in the Prednisone group). By chance allocation, the BMI was
higher in the group receiving Pioglitazone than in the group
receiving Prednisone (29.5 vs 27.9 kg/m
2; P=0.027) (Table 1).
There was no indication that significant chance imbalances had
occurred between the two groups. Further, no direct analysis
between the two groups was intended for the primary or secondary
end points. Rather, a comparison between baseline and post-
treatment results within each group was the Pilot Study’s intent.
Effect of Pioglitazone on Serum HCV RNA Titers
Pioglitazone decreased serum HCV RNA titers in overweight
HCV genotype 4, treatment naı ¨ve patients. In the Pioglitazone-
treated group, the log10 transformed HCV RNA titers were
statistically different from baseline day-0 (5.41+/20.80) on day-14
(5.24+/20.79; P,0.001) and day-7 (5.30+/20.78; P=0.009)
(Table 3), providing evidence that Pioglitazone was effective in
decreasing HCV RNA in this cohort of patients. Pioglitazone
treatment decreased the HCV RNA from baseline in 9 out of 10
subjects at day-7. The log10 HCV RNA values were also decreased
by day-4 but they were statistically not different from baseline
(5.38+/20.78; P=0.059). The log10 HCV RNA values were not
affected at day-2 by Pioglitazone treatment. Further, the decrease
in the log10 HCV RNA between day-7 and day-14 was highly
significant (mean change=0.063; 95% CI, 0.045; P,0.001)
(Table 3).
In spite of the variable baseline HCV RNA viral load,
Pioglitazone also decreased significantly the absolute HCV RNA
Pioglitazone and Hepatitis C Viral Load
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e31516levels at day-14 (mean change=205,618 IU/ml; P=0.028) and at
day-7 (mean change=152,772 IU/ml; P=0.044) (Table 3).
Effect of Pioglitazone on Indices of Insulin Resistance
Pioglitazone treatment decreased by day-14 fasting serum
glucose (Glucose-0) (mean change=8.2 mg/dL; P=0.024) as well
as the 2-hr glucose (Glucose-120 min) after an OGTT (mean
change=18.8 mg/dL; P=0.001) (Table 4).
However, Pioglitazone treatment did not affect by day-14 the
following surrogate indicators of insulin resistance and secretion:
HOMA-IR; QUICK-I; and HOMA-B. In addition, other
surrogate indicators of insulin resistance were not affected by
Pioglitazone treatment on day-14, including fasting serum insulin;
C-peptide; SHBG; resistin; and adiponectin (Table 4).
Effect of Pioglitazone on Indicators of Liver Injury and
Inflammation
Elevated serum ALT and AST values are surrogate indicators of
liver injury used in patient care and clinical research [9].
Pioglitazone treatment decreased at day-14 serum ALT levels
(mean change=7.5 IU/ml; 95% CI: 2.1 to 12.9; P=0.012) and to
a smaller degree serum AST levels (mean change=2.6 IU/ml;
95% CI: 20.6 to 5.8; P=0.096) (Table 5).
It has been suggested that serum IL-8 values are elevated in
HCV infection and that these values may reflect the effects of the
HCV on il-8 gene transcription [15]. Pioglitazone increased serum
IL-8 levels at day-14 when compared to baseline day-0 values
(mean change=2166.8 IU/ml; 95% CI: 2300.1 to 233.5;
P=0.019) (Table 6). Given the possible induction of IL-8
expression by TNF-a [15], we analyzed post-hoc their correlation
by a Pearson’s correlation coefficient. We found that there was a
relatively strong correlation between serum IL-8 and serum TNF-
a levels for day-0 and day-14 (n=20; r=0.64; 95% CI=0.28 to
0.85; P=0.002).
We found no statistically significant differences between day-0
and day-14 in serum IL-28B, TNF-a, IL-1a, IL-1b, IL-6, IL-8, IL-
10, IFN-c, MCP-1 and HGF (Table 6).
Effect of Prednisone on Serum HCV RNA
Prednisone increased the absolute HCV RNA level at day-2
(mean change=235,636 IU/ml; 95% CI 264,665 to 26,607;
P=0.021) and at day-4 (mean change=242,786 IU/ml; 95% CI
285,556 to 215.7; P=0.049) (Table 7), providing some evidence
that Prednisone may be effective in increasing HCV RNA in this
cohort of patients for that short period of time. When compared to
their baseline day-0 values, eight of 10 subjects had an increase in
Figure 1. Participant Flow. Patients with chronic Hepatitis C genotype 4 referred to the Hepatology Clinic were assessed for eligibility as described
in Methods.
doi:10.1371/journal.pone.0031516.g001
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RNA from baseline day-0 in 9 of 10 subjects at day-2 (Table 7).
However, in the Prednisone-treated group, the HCV RNA titers
expressed as log10 values on day-2 and day-4 were not statistically
different from baseline day-0 (Table 7).
Effect of Prednisone on Indices of Insulin Resistance
Prednisone treatment increased by day-4, when compared to
baseline day-0 values, fasting serum glucose (Glucose-0) (mean
change=9.0 mg/dL; 95% CI: 20.4 to 22.4; P=0.108) as well as
the 2-hr (Glucose-120 min) after an OGTT (mean chan-
ge=11.0 mg/dL; 95% CI: 17.9 to 4.1; P=0.006). Collectively,
the CI and t-tests suggest that Prednisone increased serum glucose
levels at day-4 (Table 8). However, Prednisone treatment did not
affect by day-4 other surrogate indicators of insulin resistance and
secretion (Table 8).
Effect of Prednisone on Indicators of Liver Injury and
Inflammation
Prednisone treatment did not affect at day-4 either serum ALT,
AST, IL-8 or other inflammatory mediators (Tables 9 and 10).
Adverse Events
There were no serious adverse events in either treatment group.
Mild or moderate adverse events unrelated to the allocated
treatment occurred in 20% of subjects in the Prednisone group
and in 30% of the subjects in the Pioglitazone group. There were
no significant changes from baseline during treatment in safety
laboratory tests in either treatment group.
Discussion
It was not known whether Pioglitazone and Prednisone affect
serum HCV genotype 4 RNA titers independently of PEG-
Interferon-a2/ribavirin treatment. This Study documented for the
first time that Pioglitazone (30 mg daily) decreases the serum HCV
RNA titers after a 14-day treatment in overweight subjects with
treatment naı ¨ve, chronic HCV genotype 4 infections. The statistical
differences between the mean at day-0 (baseline) and day-14 were
highly significant whether the serum HCV RNA was analyzed as
IU/ml or log10 values (Table 3). Pioglitazone treatment also
decreased the HCV genotype 4 titers on day-4 and day-7,
suggesting a rapid effect on HCV RNA titers. The comparable
mean decrease in HCV RNA for the first week and for the second
week indicates a continuing effect during the 14-day treatment.
It remains to be studied whether the rate of decrease of serum
HCV RNA titers continues after day-14 in the Pioglitazone group.
If the effects of Pioglitazone on in HCV genotype 4 RNA titers
would continue at the same rate as for the first 2 weeks, it would
achieve a clinically significant decrease of ,1 log10 in HCV RNA
titers by week-12, an important predictive timeline for a sustained
virological response in HCV treatments [16]. Given the relative
safety of Pioglitazone administration [9],[17], it could be, as a co-
adjuvant, a valuable therapeutic effect for difficult to treat HCV
genotype 4-infected patients.
Table 1. Baseline demographic and clinical characteristics of
treated subjects.
Pioglitazone
(N=10)
Prednisone
(N=10) P value
Age (years) 44 (9.3) 42(10.4) 0.592
Sex (male) 7 (70%) 8 (80%) 0.429
Ethnic origin: Arab 10 (100%) 10 (100%) 1.000
Height (cm) 173 (5.8) 175(8.7) 0.458
Weight (kg) 88.3 (9.2) 85.7(9.9) 0.550
BMI (kg/m
2) 29.5(1.5) 27.9(1.6) 0.027
HCV Genotype 4 10 (100%) 10 (100%) 1.000
HCV RNA (log10) 5.41(0.80) 5.10(0.92) 0.432
Albumin (g/dl) 3.8(0.3) 3.8(0.3) 0.939
Total bilirubin (mg/dl) 0.97(0.15) 0.90 (0.16) 0.319
ALT (IU/ml) 63 (23) 53 (14) 0.283
AST(IU/ml) 54 (17) 52 (11) 0.795
Metavir score:
A (inflammation) A1(n:5) A2(n:5) A1(n:5) A2(n:5) 1.000
F(fibrosis) F1(n:7); F2(n:3) F1(n:6); F2(n:4) 0.639
Data are means (SD) or numbers (%).
doi:10.1371/journal.pone.0031516.t001
Table 2. Baseline demographic and clinical characteristics of non-treated subjects.
Pioglitazone (N=10) P value Prednisone (N=9) P value
Age (years) 39 (4.2) 0.139 43(11.2) 0.842
Sex (male) 6 (60%) 0.660 5 (55%) 0.277
Ethnic origin: Arab 10 (100%) 1.000 9 (100%) 1.000
Height (cm) 172 (5.9) 0.706 177(8.1) 0.612
Weight (kg) 85.7 (7.6) 0.499 84.8(8.8) 0.837
BMI (kg/m
2) 28.8(2.1) 0.402 28.2(3.7) 0.818
HCV Genotype 4 10 (100%) 1.000 9 (100%) 1.000
ALT (IU/ml) 68 (10) 0.536 69 (10) 0.012
AST(IU/ml) 63 (12) 0.188 57 (8) 0.278
Metavir score:
A (inflammation) A1(n:4); A2(n:6) 0.673 A1(n:4); A2(n:5) 0.821
F(fibrosis) F1(n:5); F2(n:5) 0.388 F1(n:5); F2(n:4) 0.855
Data are means (SD) or numbers (%). P values are for comparisons between treated and untreated subjects within the same arm.
doi:10.1371/journal.pone.0031516.t002
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(40 mg daily) increases the serum HCV RNA titers after a 4-day
treatment of HCV genotype 4 overweighed patients (Table 7).
Our results with Prednisone treatment are congruent with the
recently reported increased HCV replication by corticosteroids in
the Huh-7 replicon system [13], but whether in HCV genotype 4-
infected patients, this reflects a direct corticosteroid effect on HCV
replication, an indirect effect mediated by insulin resistance, or
another mechanism is unknown. Because the Huh-7 replicon
system uses de-differentiated, tumoral liver cells that have higher
expression of glucose metabolism enzymes (glucose-6-phosphate 1-
dehydrogenase and isocitrate dehydrogenase) and of the mito-
chondrial dicarboxylate carrier [18], it may not be suitable for the
evaluation of interaction between glucose homeostasis and HCV
replication. To minimize potential adverse events associated with
the administration of Prednisone, its use was limited to 40 mg/day
for a 4-day treatment, a relatively safe and frequent standard of
care practice for some clinical conditions [19]. It remains to be
determined whether a more prolonged corticosteroid treatment in
HCV-infected patients has detrimental effects on RNA titers of
different HCV genotypes.
The subjects’ recruitment number was pre-determined by the
sample size and power analysis. An appropriate sample size was
utilized in this study, which achieved the primary and secondary
end-points with a relatively small cohort of patients. If the sample
size of the study were unnecessarily large, then the risks to the
subjects would have been excessive according to the CONSORT
statement [20]. An intention-to-treat analysis was conducted in
patients who had received $1 dose of study medication; all of
these subjects completed the study and had a subsequent efficacy
observation. Because these randomized arms were not treatments
of the HCV infection in this Study, and because during chronic
infection, the level of serum HCV RNA is in a steady state with
only minor fluctuations in untreated patients [21], instead of using
demanding placebo arms, we utilized randomization as well as de-
identified samples to blinding the investigators analyzing the
outcomes. These approaches minimize biases in executing the
study and in analyzing the outcomes according to the CONSORT
statement [20].
Triple combination therapy of Pioglitazone/PEG-Interferon-
a2/ribavirin has been used for previously treated HCV genotype 1
infection unsuccessfully in Switzerland [10] and in the USA [22],
[23] or for treatment naive HCV genotype 4 infection successfully
in Egypt [11]. It is unknown whether the beneficial effects of
Pioglitazone together with PEG-Interferon-a2/ribavirin are cir-
cumscribed to HCV genotype 4 or to treatment naı ¨ve HCV of
various genotypes. Although, the relatively low 15 mg Pioglitazone
dose used in the INSPIRED-HCV trial in Switzerland [10] could
have been insufficient to achieve efficacy, higher Pioglitazone
doses (30 mg or 45 mg per day) have been utilized in HCV
genotype 1 infection trials together with PEG-Interferon-a2/
ribavirin without improving the sustained virological response
[22], [23]. These higher Pioglitazone doses (30 mg or 45 mg per
day) have been successfully utilized to prevent the development of
type 2 diabetes in patients with impaired glucose tolerance in the
USA [8], in the treatment of HCV genotype 4 treatment naive
patients together with PEG-Interferon-a2/ribavirin in Egypt [11]
and in our Study. Further, the known effects of Pioglitazone and
Table 4. Effects of Pioglitazone on glucose homeostasis,
insulin resistance and secretion.
Test Day-0 Day-14 P value 95% CI
Glucose-0 (mg/dL) 105 (11.4) 96.8 (6.8) 0.024 1.3, 15.1
Glucose-120 (mg/dL) 120.6 (11.9) 101.8 (7.4) 0.0004 10.9, 26.7
HOMA-IR 2.71 (1.61) 2.38 (1.60) 0.326 20.95
QUICK-I 0.339 (0.031) 0.348 (0.036) 0.587 ……
HOMA-B 92.65 (57.5) 115.26 (90.85) 0.52 299.6, 54.4
Insulin (mIU/ml) 10.4 (6.2) 10.1 (7.0) 0.914 26.2, 6.8
C-peptide (nmol/L) 6.4 (9.4) 9.6 (8.5) 0.278 29.5, 3.1
SHBG (mg/ml) 3.8 (2.4) 1.7 (2.1) 0.062 2140
Adiponectin (mg/ml) 3.19 (1.32) 3.64 (1.71) 0.512 ……..
Resistin (ng/ml) 2,0 (0.2) 1,7 (0.6) 0.116 22.0
Values are mean (+/2 SD). Tests were performed as described in Methods.
doi:10.1371/journal.pone.0031516.t004
Table 5. Effects of Pioglitazone on liver injury indicators.
Day ALT (IU/L) P value 95% CI AST (IU/L) P value 95% CI
0 62.7 (23.1) 53.6 (15.6)
14 55.2(18.7) 0.0118 2.1, 12.9 51.0 (14.0) 0.0963 20.6, 5.8
Values are mean (+/2 SD). ALT and AST were determined as described in
Methods.
doi:10.1371/journal.pone.0031516.t005
Table 6. Effects of Pioglitazine on serum cytokines.
Serum Cytokine Day-0 Day-14 P value 95% CI
IL-8 (pg/ml) 181.0 (182.8) 347.8 (123.9) 0.020 2300, 233.5
IL-28B (pg/ml) 837.2 (1,068) 1,597 (955.5) 0.060 21,564, 47
TNF-a (pg/ml) 92.9 (139.6) 275.5 (268.5) 0.056 2371.7, 6.6
IL-1a (pg/ml) 136.6 (324.4) 223.6 (452.1) 0.415 2317, 143
IL-1b (pg/ml) 627.4 (1,046) 724.0 (1,098) 0.748 2760, 566
IL-2 (pg/ml) 13.9 (11.1) 16.1 (10.1) 0.632 212.3, 7.9
IL-4 (pg/ml) 10.9 (4.9) 10.4 (4.3) 0.817 24.8, 5.9
IL-6 (pg/ml) 337.9 (454.8) 560.5 (482.1) 0.280 2661, 216
IL-10 (pg/ml) 32.4 (58.2) 27.6 (44.6) 0.831 244.7, 54.3
IFN-c (pg/ml) 5.7(4.2) 7.4 (4.6) 0.403 25.9, 2.6
MCP-1 (pg/ml) 338.4(151.4) 330.6(157.9) 0.915 155, 170
HGF (pg/ml) 1008 (736) 975 (603) 0.914 2665, 732
Values are mean (+/2 SD). Serum cytokines were determined as described in
Methods.
doi:10.1371/journal.pone.0031516.t006
Table 3. Effects of Pioglitazone on serum HCV RNA titers.
Day
HCV (IU/ml
610
23)
P
value
95%
CI
HCV
log10
P
value 95% CI
0 608.2(696.4) 5.41(0.80)
2 586.9(663.9) 0.178 211.5, 53.9 5.41(0.78) 0.854 20.029
4 531.5(553.6) 0.151 233.6, 186.9 5.38(0.78) 0.077 20.002
7 455.3(504.4) 0.044 4.8, 300.7 5.30(0.78) 0.001 20.156
14 402.5(452.4) 0.029 26.6, 384.6 5.24(0.79) ,0.001 20.215
Values are mean (SD) of HCV RNA titers determined as described in Methods.
doi:10.1371/journal.pone.0031516.t003
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documented in our Study, and their effects on serum HCV RNA
titers (Table 3) suggest, but does not prove, that improving insulin
sensitivity lowers HCV RNA titers. This has been proposed by
Harrison on the basis that patients with QUICK-I values ,0.35
(equivalent to HOMA-IR.1.8) have significantly higher HCV
titers than patients with QUICK-I values .0.35 [24]. Further,
treating patients with hepatitis C genotype 1 and insulin resistance
using metformin improves insulin sensitivity and increases SVR
rate in patients who reached HOMA lower than 2 at week 24 of
therapy and in women, in whom the therapy doubled the SVR
rate [25].
The findings of our Study support the notion that sequential
treatment with Pioglitazone and PEG-Interferon-a2/ribavirin
rather than concomitant administration should be considered in
the treatment of chronic HCV genotype 4 infections, as suggested
by Serfaty and coworkers [26].
The beneficial effects of Pioglitazone treatment on glucose
homeostasis have been well documented in patients with impaired
glucose tolerance [8], and it was also reported in triple
combination therapy of Pioglitazone/PEG-Interferon-a2/ribavi-
rin in patients with HCV genotype 1 or 4 [10],[11]. In our Study,
Pioglitazone treatment decreased by day-14 and Prednisone
increased by day-4 fasting serum glucose as well as the 2-hr
glucose after an OGTT (Table 4 and 8). However, when
compared to baseline day-0 values, neither Pioglitazone treatment
at day-14 nor Prednisone treatment at day-4 affected HOMA-IR;
QUICK-I; and HOMA-B, surrogate indicators of insulin
resistance and secretion (Tables 4 and 8). It would probably
require a more prolonged treatment with Pioglitazone and
Prednisone to induce changes in these surrogate indicators of
insulin resistance and secretion [26].
Elevated serum ALT and AST values are surrogate indicators of
liver injury used in patient care and clinical research [9].
Pioglitazone treatment decreased at day-14 serum ALT levels
and to a smaller degree serum AST levels (Table 5). Additional
insights into the mechanisms of Pioglitazone on liver injury in
chronic HCV infection would require assessment of liver biopsies
before and after prolonged treatment since the effects on serum
ALT were clinically modest at day-14. Prednisone treatment did
not affect at day-4 serum ALT or AST levels (Table 9).
Many experimental and clinical studies have shown that PPARc
signaling has anti-inflammatory properties in the liver [27].
Interestingly, HCV infection in Huh-7 cells and in humans
inhibits PPARc expression and function [27]. Two studies
suggested therapeutic effects of bezafibrate, a non-selective agonist
of PPAR a/d/c, during chronic HCV infection. Patients with
HCV genotype 1 and 2 unresponsive to interferon therapy were
treated for 8 weeks or 6 months with bezafibrate [28], [29]. At
endpoint, HCV viral load (20.5 log10) and ALT were statistically
significantly decreased, suggesting anti-inflammatory and antiviral
activities of the PPAR a/d/c signaling pathways in patients with
chronic HCV infection. Given the non-selective nature of the
PPAR a/d/c agonist, it is difficult to determine whether induction
of PPARc pathways occurred and played a role in the decreased
HCV RNA.
Table 7. Effects of Prednisone on serum HCV RNA titers.
Day
HCV (IU/ml
610
23)
P
value
95%
CI
HCV
log10
P
value
95%
CI
0 498.0(805.3) 5.10(0.92)
2 533.7(834.4) 0.0215 264.6,
26.6
5.14(0.94) 0.059 0.08
4 540.8(855.2) 0.0499 285.5,
215.7
5.13(0.92) 0.18 0.03
Values are mean (SD). HCV RNA titers were determined as described in
Methods.
doi:10.1371/journal.pone.0031516.t007
Table 8. Effects of Prednisone on glucose homeostasis,
insulin resistance and secretion.
Test Day-0 Day-4 P value 95% CI
Glucose-0 (mg/dL) 88.0 (14.7) 97.0 (12.9) 0.107 220.4, 2.4
Glucose-120 (mg/dL) 96.4 (10.5) 107.4 (12.3) 0.0055 217.9,
24.1
HOMA-IR 1.73 (1.06) 2.55(1.96) 0.162 21.06
QUICK-I 0.358(0.022) 0.345 (0.032) 0.275
HOMA-B 95.48 (49.35) 115.86 (95.96) 0.623 220.38
Insulin (mIU/ml) 7.5(3.9) 10.5 (8.2) 0.374 210.2, 4.4
C-peptide (nmol/L) 11.3 (8.9) 4.1 (1.3) 0.061 20.5, 14.9
SHBG (mg/ml) 3.4(2.5) 2.7 (2.2) 0.591 22.4
Adiponectin (mg/ml) 5.9 (8.2) 2.6 (2.1) 0.306 24.5
Resistin (ng/ml) 3.4 (2.5) 2.7 (2.2) 0.591 22.4
Values are mean (+/2 SD). Tests were performed as described in Methods.
doi:10.1371/journal.pone.0031516.t008
Table 9. Effects of Prednisone on liver injury indicators.
Day ALT (IU/L) P value 95% CI AST (IU/L) P value 95% CI
0 53.2 (14.4) 52.0(11.3)
4 55.7 (15.7) 0.080 5.4, 20.4 52.2 (12.8) 0.896 3.6, 23.2
Values are mean (+/2 SD). ALT and AST were determined as described in
Methods.
doi:10.1371/journal.pone.0031516.t009
Table 10. Effects of Prednisone on serum cytokines.
Serum Cytokine Day-0 Day-4 P value 95% CI
IL-8 (pg/ml) 123.1 (163.5) 159.5 (185.1) 0.353 2123, 50
IL-28B (pg/ml) 485.9(876.4) 610.8 (857.7) 0.120 2292, 42
TNF-a(pg/ml) 146.6 (268.8) 146.1 (284.4) 0.996 2275, 276
IL-1a (pg/ml) 80.1 (208.3) 19.2(38.3) 0.450 2119, 240
IL-1b (pg/ml) 92.7 (120.3) 144.8 (293.0) 0.682 2348, 244
IL-2 (pg/ml) 11.8 (9.8) 11.3 (9.6) 0.742 23.1, 4.2
IL-4 (pg/ml) 19.3 (19.1) 10.9 (7.2) 0.329 210.5, 27.3
IL-6 (pg/ml) 292.8 (445.7) 359.9 (501.4) 0.492 2282, 149
IL-10 (pg/ml) 67.4 (106.8) 30.8 (51.2) 0.144 216.1, 89.4
IFNc (pg/ml) 13.9 (24.9) 4.9 (4.3) 0.342 211.9, 29.9
MCP-1 (pg/ml) 232.7 (126.1) 266.8 (112.8) 0.469 2139, 71
HGF (pg/ml) 1345 (800) 1022 (681) 0.483 2711, 1357
Values are mean (+/2 SD). Serum cytokines were determined as described in
Methods.
doi:10.1371/journal.pone.0031516.t010
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inflammation in patients with non-alcoholic steatohepatitis [9] and
this has been attributed to the beneficial effects of Pioglitazone on
insulin signaling [8]. An alternative explanation is a possible direct
effect of Pioglitazone either as a PPARc agonist or through other
mechanisms on liver injury, independently of its insulin sensitizing
actions [8]. Indeed, PPARc agonists induce alternative, anti-
inflammatory M2 macrophage activation [30], possibly linking
insulin sensitivity with decreased liver injury in patients with HCV
infection. At the molecular level, insulin resistance is promoted by
a transition from an anti-inflammatory macrophage M2 state
maintained by STAT6 and PPARc to a pro-inflammatory
macrophage M1 state driven by C/EBPb and NF-kB activation
and other transcription factors that play important roles in innate
immunity [30]. Relevant to the management of HCV infected
patients, liver fibrogenesis is expected to be ameliorated by PPARc
signaling [31] as well as by decreased inflammatory pathways
arising from M2 macrophages [32] and resulting in decreased
activation of hepatic stellate cells [33].
Pioglitazone increased serum IL-8 levels at day-14 when
compared to baseline day-0 values (Table 6). Serum IL-8 values
are elevated in HCV infection [34] and these values may reflect
the effects of the HCV on il-8 gene transcription as well as its
induction by TNFa [15]. We found that there was a relatively
strong correlation between serum IL-8 and serum TNF-a levels for
day-0 and day-14. Although it has been suggested that elevated
levels of serum IL-8 may be associated with HCV resistance to
Interferon-a2 therapy, the clinical or biological significance of the
elevated serum IL-8 in HCV genotype 4 patients treated with
Pioglitazone remains to be determined.
Prednisone did not affect serum IL-8 levels at day-4 when
compared to baseline day-0 values (Table 10). We found no
differences between day-0 and day-14 in the Pioglitazone group
and day-4 in the Prednisone group in other inflammatory markers
such as serum IL-28B, TNF-a, IL-1a, IL-1b, IL-6, IL-8, IL-10,
IFN-c, MCP-1 and HGF (Tables 6 and 10). The lack of changes
in IL-28B (IFN-c3) is relevant since genetic variation in IL-28B
affects the spontaneous clearance of HCV in patients [35].
Our study has some limitations: i] there were, as expected,
clinically modest decreases in HCV RNA at day-14 in the
Pioglitazone group; ii] the relatively small cohort could introduce
potential biases; and iii] the findings may not be applicable for
patients with HCV genotype 4 in other ethnic groups
It remains to be elucidated whether the effects of Pioglitazone
also occur in HCV genotype 4 infections in previously treated
patients. The novel findings of our Study provide the foundation
for basic and clinical investigations on the molecular mechanisms
responsible for the Pioglitazone-induced decrease in HCV
genotype 4 RNA titers. Future research should characterize
whether the effects of Pioglitazone on HCV genotype 4 RNA titers
are mediated indirectly by insulin signaling pathways or directly by
affecting HCV genotype 4 hepatocyte entry and/or replication.
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